研究协议:应用程序和同行支持健康的未来和生活与糖尿病 (APHLID-M)
K O Mathews1, F MacMillan2, V Wong3
1School of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Contemporary clinical trials communications
|May 7, 2025
概括
这项研究测试了一款智能手机应用程序,用于患有糖尿病的年轻人,以改善心理健康和自我管理. 在APHLID-M试验中,研究了在糖尿病护理中改善幸福感的数字工具.
科学领域:
- 数字健康干预措施 数字健康干预措施
- 青少年和年轻人的药物
- 糖尿病管理 糖尿病管理
背景情况:
- 精神健康状况在患有糖尿病的年轻人中普遍存在,影响自我管理并增加并发症风险.
- 关于智能手机应用程序的有效性存在有限的证据,这些应用程序结合了糖尿病和心理健康支持.
- 应用程序和同行支持健康未来和与糖尿病健康生活 (APHLID-M) 研究解决了这一差距.
研究的目的:
- 评估智能手机应用程序与心理健康支持相结合的有效性,以减少患有糖尿病的年轻成年人的心理痛苦.
- 评估应用程序对糖尿病自我管理和血糖控制 (HbA1c) 的影响.
- 探索数字技术在增强患有糖尿病的年轻人心理健康和身体健康方面的作用.
主要方法:
- 一个多中心的,两个随机对照试验 (RCT) 设计,涉及年轻成年人年龄16-30岁的糖尿病.
- 参与者接受心理健康状况 (MHC) 查,并分配到一个主要的RCT (MHC组) 或一个嵌套探索性RCT (非MHC组).
- 干预涉及智能手机应用程序与糖尿病和心理健康资源,以及同行支持,与接受标准护理和同行支持的对照组相比.
主要成果:
- 主要结果是心理困扰的变化,用克斯勒心理困扰量表 (K10) 来衡量.
- 二次结果包括HbA1c水平的变化,在基线和6个月评估.
- 招聘目标为主要RCT的142名参与者.
结论:
- 预计APHLID-M研究将对数字健康工具对改善糖尿病年轻人精神和身体健康结果的实用性提供重要的见解.
- 调查结果将为开发和实施技术辅助干预措施为这一弱势群体提供信息.
- 这项研究有助于了解如何通过综合数字支持来提高福祉和糖尿病管理.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
212
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
212
01:14SBAR II: Application of SBAR
4.2K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.2K
01:16Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127